Microbubble-assisted p53, RB, and p130 gene transfer in combination with radiation therapy in prostate cancer

Current Gene Therapy

Volumn 13, Issue 3, 2013, Pages 163-174

  Nande, Rounak ^a   Greco, Adelaide ^a,b,c   Gossman, Michael S ^d   Lopez, Jeffrey P ^d   Claudio, Luigi ^e   Salvatore, Marco ^b   Brunetti, Arturo ^b   Denvir, James ^a   Howard, Candace M ^a   Claudio, Pier Paolo ^a  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^d Tri State Regional Cancer Center   (United States)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apoptosis induction; External beam radiation; Microbubbles; P130; P53; Prostate cancer; Radiation; RB; Retinoblastoma; Systemic targeted viral gene delivery; Tumor suppressor gene; Ultrasound

Indexed keywords

ADENOVIRUS VECTOR; ECHO CONTRAST MEDIUM; PROTEIN P130; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BRIGHT FIELD MICROSCOPY; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; DNA DAMAGE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MICROBUBBLE; MOUSE; NONHUMAN; PHASE CONTRAST MICROSCOPY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR VOLUME; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BENZOTHIAZOLES; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; GENE TRANSFER TECHNIQUES; GENES, P53; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, INBRED BALB C; MICROBUBBLES; PROSTATIC NEOPLASMS; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA-LIKE PROTEIN P130; TRANSGENES; ULTRASONOGRAPHY; X-RAYS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 84878659638     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523211313030001     Document Type: Article

References (51)

1. Dash R, Azab B, Shen XN, et al. Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic. Discov Med 2011; 11: 46-56.
2. Howard CM, Forsberg F, Minimo C, et al. Ultrasound guided site specific gene delivery system using adenoviral vectors and commercial ultrasound contrast agents. J Cell Physiol 2006; 209: 413-21.
3. Greco A, Di Benedetto A, Howard CM, et al. Eradication of therapy-resistant human prostate tumors using an ultrasoundguided site-specific cancer terminator virus delivery approach. Mol Ther 2010; 18: 295-306.
4. Hernot S, Klibanov AL. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev 2008; 60: 1153-66.
5. Tsai CH, Lin JH, Ju CP. Gamma-radiation-induced changes in structure and properties of tetracalcium phosphate and its derived calcium phosphate cement. J Biomed Mater Res B Appl Biomater 2007; 80: 244-52.
6. Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 1995; 14: 3-15.
7. Udayakumar T, Shareef MM, Diaz DA, Ahmed MM, Pollack A. The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy. Semin Radiat Oncol 2010; 20: 258-66.
8. Algan O, Stobbe CC, Helt AM, Hanks GE, Chapman JD. Radiation inactivation of human prostate cancer cells: the role of apoptosis. Radiat Res 1996; 146: 267-75.
9. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59: 928-42.
10. Bromfield GP, Meng A, Warde P, Bristow RG. Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer Prostatic Dis 2003; 6: 73-85.
11. Bajgelman MC, Strauss BE. The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53. Prostate 2006; 66: 1455-62.
12. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 1992; 89: 7491-5.
13. Bowen C, Spiegel S, Gelmann EP. Radiation-induced apoptosis mediated by retinoblastoma protein. Cancer Res 1998; 58: 3275-81.
14. Sasaki R, Shirakawa T, Zhang ZJ, et al. Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. Int J Radiat Oncol Biol Phys 2001; 51: 1336-45.
15. Bowen C, Birrer M, Gelmann EP. Retinoblastoma proteinmediated apoptosis after gamma-irradiation. J Biol Chem 2002; 277: 44969-79.
16. Crook JM, Raymond Y, Salhani D, Yang H, Esche B. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol 1995; 37: 35-42.
17. Pucci B, Claudio PP, Masciullo V, et al. pRb2/p130 promotes radiation-induced cell death in the glioblastoma cell line HJC12 by p73 upregulation and Bcl-2 downregulation. Oncogene 2002; 21: 5897-905.
18. Stevens CW, Zeng M, Cerniglia GJ. Ionizing radiation greatly improves gene transfer efficiency in mammalian cells. Hum Gene Ther 1996; 7: 1727-34.
19. Pitt WG, Husseini GA, Staples BJ. Ultrasonic drug delivery--a general review. Expert Opin Drug Deliv 2004; 1: 37-56.
20. Howard CM. The role of ultrasound contrast agents in gene therapy. Applied Radiology 2004; 33, suppl: 126-35.
21. Swisher SG, Roth JA, Komaki R, et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003; 9: 93-101.
22. Zhang H, Li J, Wang YY, et al. Retinoblastoma 94 enhances radiation treatment of esophageal squamous cell carcinoma in vitro and in vivo. J Radiat Res 2012; 53: 117-24.
23. Vogiatzi P, Cassone M, Claudio L, Claudio PP. Targeted therapy for advanced prostate cancer: Looking through new lenses. Drug News Perspect 2009; 22: 593-601.
24. Vogiatzi P, Claudio PP. Efficacy of abiraterone acetate in postdocetaxel castration-resistant prostate cancer. Expert Rev Anticancer Ther 2010; 10: 1027-30.
25. Teyssier F, Bay JO, Dionet C, Verrelle P. Cell cycle regulation after exposure to ionizing radiation. Bull Cancer 1999; 86: 345-57.
26. Lee JT, Lehmann BD, Terrian DM, et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008; 7: 1745-62.
27. Claudio PP, Zamparelli A, Garcia FU, et al. Expression of cellcycle- regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma. Clin Cancer Res 2002; 8: 1808-15.
28. Claudio PP, Tonini T, Giordano A. The retinoblastoma family: twins or distant cousins? Genome Biol 2002; 3: reviews3012.
29. Cowen D, Salem N, Ashoori F, et al. Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. Clin Cancer Res 2000; 6: 4402-8.
30. Lehmann BD, Brooks AM, Paine MS, et al. Distinct roles for p107 and p130 in Rb-independent cellular senescence. Cell Cycle 2008; 7: 1262-8.
31. Bott SR, Arya M, Kirby RS, Williamson M. p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation. Prostate Cancer Prostatic Dis 2005; 8: 321-6.
32. Willis A, Jung EJ, Wakefield T, Chen X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 2004; 23: 2330-8.
33. Helmbold H, Deppert W, Bohn W. Regulation of cellular senescence by Rb2/p130. Oncogene 2006; 25: 5257-62.
34. Harrington EA, Bruce JL, Harlow E, Dyson N. pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc Natl Acad Sci U S A 1998; 95: 11945-50.
35. Haas-Kogan DA, Kogan SC, Levi D, et al. Inhibition of apoptosis by the retinoblastoma gene product. EMBO J 1995; 14: 461-72.
36. Helmbold H, Komm N, Deppert W, Bohn W. Rb2/p130 is the dominating pocket protein in the p53-p21 DNA damage response pathway leading to senescence. Oncogene 2009; 28: 3456-67.
37. DuPree EL, Mazumder S, Almasan A. Genotoxic stress induces expression of E2F4, leading to its association with p130 in prostate carcinoma cells. Cancer Res 2004; 64: 4390-3.
38. Dummer R, Bergh J, Karlsson Y, et al. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors. Cancer Gene Ther 2000; 7: 1069-76.
39. Yen N, Ioannides CG, Xu K, et al. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). Cancer Gene Ther 2000; 7: 530-6.
40. Rochlitz CF. Gene therapy of cancer. SMW 2001; 131: 4-9.
41. Goldberg BB, Liu JB, Forsberg F. Ultrasound contrast agents: a review. Ultrasound Med Biol 1994; 20: 319-33.
42. Bhatia VK, Senior R. Contrast echocardiography: evidence for clinical use. J Am Soc Echocardiogr 2008; 21: 409-16.
43. Colletier PJ, Ashoori F, Cowen D, et al. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. Int J Radiat Oncol Biol Phys 2000; 48: 1507-12.
44. Yang ZX, Wang D, Wang G, et al. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin Oncol 2010; 136: 625-30.
45. Lupold SE, Rodriguez R. Adenoviral gene therapy, radiation, and prostate cancer. Rev Urol 2005; 7: 193-202.
46. Nande R, Di Benedetto A, Aimola P, et al. Targeting a newly established spontaneous feline fibrosarcoma cell line by gene transfer. PloS One 2012; 7: e37743.
47. Aimola P, Carmignani M, Volpe AR, et al. Cadmium induces p53- dependent apoptosis in human prostate epithelial cells. PloS One 2012; 7: e33647.
48. Mukerjee R, Claudio PP, Chang JR, Del Valle L, Sawaya BE. Transcriptional regulation of HIV-1 gene expression by p53. Cell Cycle 2010; 9: 4569-78.
49. Claudio PP, Cui J, Ghafouri M, et al. Cdk9 phosphorylates p53 on serine 392 independently of CKII. J Cell Physiol 2006; 208: 602-12.
50. Gossman MS, Das IJ, Sharma SC, et al. A novel phantom model for mouse tumor dose assessment under MV beams. Health Phys 2011; 101: 746-53.
51. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-10.